DMR-002 / Damora Therapeutics - LARVOL DELTA

Anticipated Milestones (GlobeNewswire) - "DMR-002 (Fc enhanced, half-life extended anti-mutCALR monoclonal antibody): first regulatory submission expected in the second half of 2026; DMR-003 (T-cell engager anti-mutCALR/CD3 bispecific antibody): first regulatory submission expected in 2027; Two clinical proof-of-concept datasets for DMR-001 (Fc null, half-life extended anti-mutCALR monoclonal antibody) anticipated beginning mid-2027."

CALR • IND • New trial • Myeloproliferative Neoplasm

Anticipated Milestones (GlobeNewswire) - "Damora anticipates the following upcoming milestones across its mutCALR programs...: (i) DMR-002: first regulatory submission expected in the second half of 2026; (ii) DMR-003: first regulatory submission expected in 2027; (iii) Two clinical proof-of-concept datasets for DMR-001 anticipated beginning mid-2027."

CALR • Clinical data • IND • Essential Thrombocythemia • Myelofibrosis

Follow-on candidates DMR-002 and DMR-003 are designed to broaden coverage across the mutCALR disease spectrum, with planned regulatory filings in the second half of 2026 and in 2027, respectively. (StockTitan.net)

CALR • IND • Myeloproliferative Neoplasm

Damora anticipates the following upcoming milestones across its mutCALR programs (GlobeNewswire) - "Submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) or a clinical trial application (CTA) to a regulatory authority in another country for DMR-001 in mid-2026; Submit an IND or CTA for DMR-002 in the second half of 2026; Submit an IND or CTA for DMR-003 in 2027; Present two clinical proof-of-concept datasets for DMR-001 beginning mid-2027."

CALR • IND • New trial • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm

Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders (GlobeNewswire) - "Combined with gross proceeds of approximately $316 million from the Company’s recently closed public offering in February 2026, Damora plans to rapidly advance its pipeline of mutant calreticulin (mutCALR)-targeted therapeutics in essential thrombocythemia (ET) and myelofibrosis (MF), beginning with lead program DMR-001....The Company’s additional anti-mutCALR pipeline therapies, DMR-002 and DMR-003, enable portfolio optionality to address the full spectrum of patients with mutCALR-driven MPNs."

CALR • Financing • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm

Galecto Announces Acquisition of Damora Therapeutics (GlobeNewswire) - "The acquisition gives the combined company a pipeline covering a broad spectrum of hematological cancers and leverages the deep expertise of both teams, and positions Galecto to advance Damora’s complementary assets for people living with blood cancers....The private placement resulted in gross proceeds to Galecto of approximately $284.9 million and is expected to fund operations into 2029, enabling advancement of Damora’s lead program, DMR-001, through key Phase 1 proof-of-concept data expected in 2027, as well as pipeline programs, DMR-002 and DMR-003, into Phase 1 studies."

M&A • P1 data • Essential Thrombocythemia • Myelofibrosis